Video Shorts
1:52
ASCO GI 2026 Highlights
10 months ago
0:45
The Use of Measurements in Oncology to Define Clinical Utility
10 months ago
by
Maurie Markman, MD
0:57
FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
10 months ago
by
Christof Vulsteke, MD, PhD
1:09
AI-Powered Tools May Accelerate Developments in Precision Oncology for GI Cancer
10 months ago
by
William A. Hall, MD
0:50
Anderson Underscores Benefits of Daratumumab Combination in MRD-Postitive Multiple Myeloma
10 months ago
by
Larry Anderson, MD, PhD
1:04
RFS Outcomes With Adjuvant Pembrolizumab vs Placebo After Complete Radiological Response in HCC
10 months ago
by
Stephen Lam Chan, MBBS, MD
1:08
Hahn Highlights The Promise of Angiogenesis Targeted Therapies in RCC
10 months ago
by
Andrew W. Hahn, MD
0:21
Hirbe Previews Exciting Progress With Predictive Biomarker Research at SNO 2025
a year ago
by
Angela C. Hirbe, MD, PhD
0:25
Schaff Spotlights Key Research in Leptomeningeal Metastases at SNO 2025
a year ago
by
Lauren Shaff, MD
1:38
20th Annual New York Lung Cancers Symposium
a year ago
by
Benjamin Herzberg, MD(+3 more)
0:57
Unpacking Data From the Phase 3 ROSELLA Study
a year ago
by
Vanda Salutari, MD
0:32
The Significance of OptiTROP-Lung04 for TROP-2 ADCs in Lung Cancer
a year ago
by
Pasi A. Jänne, MD, PhD
1:34
Precision Strategies and Targeted Combinations in GU Oncology From ESMO 2025
a year ago
by
Andrea Necchi, MD(+1 more)
1:32
Breaking Down the Surgical Management of Known Metastatic Cancer
a year ago
by
Maurie Markman, MD
1:03
The Multidisciplinary Use of Radiation, Systemic Therapy, and Surgery in Oncology
a year ago
by
Maurie Markman, MD
1:41
Examining the Role of Taxpayer-Funded Clinical Trials in Cancer Care
a year ago
by
Primo N. Lara Jr, MD
0:32
Unpacking the Phase 3 KEYNOTE-905/EV-303 Trial
a year ago
by
Daniel P. Petrylak, MD
0:52
The Role of AI for Oncology Insurance Prior Authorization Processes
a year ago
by
Kate Baker, MD, MMHC
0:52
The Evolving CLL Treatment Paradigm
a year ago
by
Aaron Gerds, MD, MS
0:54
The Importance of Increasing Global Access to Biomarker Testing in Lung Cancer
a year ago
by
Christian Rolfo, MD, PhD
1:04
Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance
a year ago
by
R. Lor Randall, MD, FACS
0:1.55
Experts Align on Priorities in Lung Cancer Care At Global BTG Lung 2025
a year ago
by
OncLive
1:03
The Evolution of Surgical Oncology
a year ago
by
Maurie Markman, MD
1:28
The Reality of Missed Genetic Testing
a year ago
by
Maurie Markman, MD
1:04
What to Know About the FDA Approval of BVd in Multiple Myeloma
a year ago
by
Surbhi Sidana, MD
0:1.55
Go Behind-the-Scenes With OncLive at ESMO 2025
a year ago
by
OncLive
0:30
Can AI Insights Unlock Broader Access to NGS and Targeted Therapy?
a year ago
by
Brian P. Mulherin, MD
0:24
Global Voices, Shared Vision: Aligning Clinical Priorities in Lung Cancer
a year ago
by
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
1:11
The FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC
a year ago
by
Armeen Mahvash, MD
2:40
Previewing the Phase 2 NorthStar Trial Ahead of the 2025 ESMO Congress
a year ago
by
Sagus Sampath, MD
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026
2
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
3
Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma
4
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma
5